The short answer
ClinicalTrials.gov lists a pre-approval expanded access record for retatrutide (NCT07629401) with a status of available. Expanded access is a regulated route by which a sponsor may supply an unapproved medicine to specific patients outside a trial, through their physician. It is not a purchase route and not a general availability signal.
Key facts
- Registration
- NCT07629401
- Type
- Pre-approval expanded access
- Status
- Available
- Sponsor
- Eli Lilly and Company
- Not a
- Clinical trial (no phase, no endpoints)
- Access route
- Through a treating physician to the sponsor
- Regulatory status
- Retatrutide remains unapproved
What expanded access is
Expanded access, sometimes called compassionate use, is a regulated pathway allowing a patient with a serious condition to receive an investigational medicine outside a clinical trial. It requires a treating physician to request it, the sponsor to agree to supply, and regulatory and ethics oversight. It exists for patients who cannot enrol in a trial and have no satisfactory alternative.
Why it appears on a trials registry at all
ClinicalTrials.gov records expanded access programmes alongside trials, but they are a different kind of record, no phase, no enrolment target, no primary outcome measure, because nothing is being measured. The status field reads available rather than recruiting. Seeing it in a search for retatrutide trials and reading it as another study is an easy mistake.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What it does not mean
It does not mean retatrutide is approved, approaching approval, or generally obtainable. It does not create a supply route for anyone outside the defined pathway, and it is not something an individual can apply to directly. The compound remains investigational in every jurisdiction, and its regulatory status is unchanged by the existence of this record.
Why it still matters
Expanded access records get cited in discussion as evidence that a compound is becoming available. It is a reasonable-sounding inference and it is wrong. The programme is a narrow clinical mechanism operating under sponsor and regulator control, and conflating it with availability is the sort of error that propagates quickly once someone makes it.
The distinction that matters here
Material supplied for laboratory research is not connected to this programme in any way. It is not the same supply, not an alternative to it, and not a route into it. Research material is supplied for laboratory use only, and nothing about an expanded access listing changes that.
Frequently asked questions
Can I get retatrutide through expanded access?
It is not a route individuals can pursue directly. Expanded access requires a treating physician's request, sponsor agreement, and regulatory oversight, for patients meeting defined criteria.
Does an expanded access listing mean approval is close?
No. It is a separate mechanism from approval and says nothing about the timing of any regulatory decision.
Why does it show on ClinicalTrials.gov without a phase?
Because it is not a trial. Nothing is being measured, so there is no phase, enrolment target or outcome measure.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- The Compounded GLP-1 CrackdownThe FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List in April 2026, closing the last legal route for mass compounding.
- MHRA Drug Safety Update: Semaglutide and NAIONOn 5 February 2026 the MHRA warned of a likely association between semaglutide and NAION, a rare optic neuropathy, estimated at up to 1 in 10,000 users.
- Target Trial Emulation: Making Observational Data BehaveA method for analysing routine health records as though a trial had been designed. Why it exists, what it fixes, and what it cannot fix.
- What the Cardiovascular and Kidney Data Actually IsA 2025 target trial emulation examined GLP-1 outcomes in adults with obesity. What that design can support, and how it differs from a randomised trial.
- Tirzepatide in Heart Failure With Preserved Ejection FractionA target trial emulation in Nature Communications examined tirzepatide in HFpEF. Why this population is studied and what the design supports.